DOCSLIB.ORG

Julius Baer Multistock Société D'investissement À Capital Variable

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Julius Baer Multistock Société D'investissement À Capital Variable Julius Baer Multistock Société d'Investissement à Capital Variable Semi-annual Report as at 31 December 2014 (unaudited) Subscriptions are carried out solely on the basis of the current prospectus or the key investor information, in conjunction with the latest annual report and the latest semi-annual report if published thereafter. The articles of association, the valid prospectus and the key investor information, the annual and semi-annual reports, as well as the information based on the SFAMA guidelines on transparency with regard to management fees, may be obtained free of charge from the representative in Switzerland and/or from the respective paying agent. In case of differences between the German version and the translation, the German version shall be the authentic text. AN INVESTMENT FUND DOMICILED IN LUXEMBOURG Representative in Switzerland: Swiss & Global Asset Management AG, Hardstraße 201, P.O. Box, CH - 8037 Zurich Paying agent in Switzerland: Bank Julius Bär & Co. AG, Bahnhofstraße 36, P.O. Box, CH - 8010 Zurich Paying agent in Germany: DekaBank Deutsche Girozentrale, Hahnstraße 55, D - 60528 Frankfurt / Main Information agent in Germany: Swiss & Global Asset Management Kapital AG, Taunusanlage 15, D - 60325 Frankfurt / Main Paying agent in Austria: Erste Bank der oesterreichischen Sparkassen AG, Graben 21, A - 1010 Vienna Trade and Companies Register number: R.C.S. Luxembourg B-32188 Contents Page Organisation and Management 4 Notes to the Semi-annual Report 6 Additional Information for Shareholders in Switzerland 15 Julius Baer Multistock (Umbrella fund) 22 Julius Baer Multistock - ABSOLUTE RETURN EUROPE EQUITY FUND 24 Julius Baer Multistock - AFRICA FOCUS FUND 33 Julius Baer Multistock - AGRICULTURE FUND 38 (as at 18 December 2014: merger into Julius Baer Multistock - NATURAL RESOURCES FUND) Julius Baer Multistock - ASIA FOCUS FUND 40 Julius Baer Multistock - CHINA EVOLUTION FUND 45 Julius Baer Multistock - EASTERN EUROPE FOCUS FUND 49 Julius Baer Multistock - ENERGY TRANSITION FUND 55 Julius Baer Multistock - EURO LARGE CAP STOCK FUND 60 Julius Baer Multistock - EUROLAND VALUE STOCK FUND 65 Julius Baer Multistock - EUROPE FOCUS FUND 70 Julius Baer Multistock - EUROPE SMALL & MID CAP STOCK FUND 74 Julius Baer Multistock - GERMAN VALUE STOCK FUND 79 Julius Baer Multistock - GLOBAL EMERGING MARKETS STOCK FUND 83 Julius Baer Multistock - GLOBAL EQUITY INCOME FUND 89 Julius Baer Multistock - HEALTH INNOVATION FUND 95 Julius Baer Multistock - INFRASTRUCTURE FUND 100 Julius Baer Multistock - JAPAN STOCK FUND 105 Julius Baer Multistock - LUXURY BRANDS FUND 111 Julius Baer Multistock - NATURAL RESOURCES FUND 115 Julius Baer Multistock - NEW WORLD OPPORTUNITIES FUND 120 Julius Baer Multistock - RUSSIA FUND 124 (as of 29 July 2014: merger into Julius Baer Multistock - EASTERN EUROPE FOCUS FUND) Julius Baer Multistock - SWISS SMALL & MID CAP STOCK FUND 126 Julius Baer Multistock - SWISS STOCK FUND 130 Julius Baer Multistock - US LEADING STOCK FUND 134 Contents Julius Baer Multistock - US VALUE STOCK FUND 140 Addresses 145 ALFI Code of Conduct The Board of Directors confirms that the Fund adhered to the rules of the ALFI Code of Conduct for Luxembourg investment funds in all significant aspects during the accounting period from 1 July 2014 to 31 December 2014. Organisation and Management The Company has its registered office at Michel Malpas 25, Grand-Rue Independent Director L - 1661 Luxembourg Luxembourg, Grand Duchy of Luxembourg Board of Directors of the Company Michele Porro Member of the Group Management Board, GAM Group Chairman: Region Head Continental Europe Martin Jufer Swiss & Global Asset Management Member of the Group Management Board, GAM Group Zurich, Switzerland Head of Operations Swiss & Global Asset Management Managing Directors of the Management Company Zurich, Switzerland Ewald Hamlescher Members: Managing Director Me Freddy Brausch Swiss & Global Asset Management (Luxembourg) S.A. Partner Luxembourg, Grand Duchy of Luxembourg Linklaters LLP Luxembourg, Grand Duchy of Luxembourg Steve Kieffer Managing Director Andrew Hanges Swiss & Global Asset Management (Luxembourg) S.A. Member of the Group Management Board, GAM Group Luxembourg, Grand Duchy of Luxembourg Head of Operations GAM and Region Head UK GAM (UK) Ltd. London, United Kingdom Investment Manager Jean-Michel Loehr For the Julius Baer Multistock - INFRASTRUCTURE FUND: Independent Director Macquarie Capital Investment Management (Australia) Limited Luxembourg, Grand Duchy of Luxembourg Level 7, No. 1 Martin Place 2000 Sydney, Australia Dirk Spiegel Managing Director For the Julius Baer Multistock - AGRICULTURE FUND: Head of Legal & Compliance Wellington Management Company, LLP Swiss & Global Asset Management AG 75 State Street Zurich, Switzerland Boston, Massachusetts 02109, USA (until 18 December 2014) Management Company and Domiciliary Agent Wellington Management International Ltd. Swiss & Global Asset Management (Luxembourg) S.A. Cardinal Place 25, Grand-Rue 80 Victoria Street L - 1661 Luxembourg London SW1E 5JL (since 19 December 2014) Board of Directors of the Management Company For the Julius Baer Multistock - US LEADING STOCK FUND: Chairman: Sarofim International Management Company Martin Jufer Two Houston Center Member of the Group Management Board, GAM Group Suite 2907 Head of Operations 909 Fannin St. Swiss & Global Asset Management Houston, Texas 77070, USA Zurich, Switzerland For all other sub-funds: Members: Swiss & Global Asset Management AG Andrew Hanges Hardstraße 201 Member of the Group Management Board, GAM Group P.O. Box Head of Operations GAM and Region Head UK GAM (UK) Ltd. CH - 8037 Zurich London, United Kingdom The investment managers may hire investment advisers to assist them in Yvon Lauret managing individual sub-funds. Independent Director Luxembourg, Grand Duchy of Luxembourg 4 Organisation and Management Advisory company Belgium: RBC Investor Services Belgium S.A. Swiss & Global Advisory S.A. Place Rogier 11 25, Grand-Rue B - 1210 Brussels L - 1661 Luxembourg France: Caceis Bank Custodian, Administrator, Principal Paying Agent, 1-3, Place Valhubert Registrar and Transfer Agent F - 75013 Paris State Street Bank Luxembourg S.A. United Kingdom: 49, Avenue J.F. Kennedy GAM Sterling Management Ltd. L - 1855 Luxembourg 12 St. James’s Place London, SW1A 1NX Distributors Ireland: The Company and/or the Management Company has appointed and GAM Fund Management Limited may appoint further distributors authorised to sell the shares in one or George’s Court more jurisdictions. 54-62 Townsend Street Dublin 2 Auditor Ireland PricewaterhouseCoopers, Société coopérative Liechtenstein: 2, Rue Gerhard Mercator LGT Bank in Liechtenstein AG L - 2182 Luxembourg Herrengasse 12 FL - 9490 Vaduz Legal Adviser Spain: Linklaters LLP ATL12 Capital Inversiones A.V., S.A. 35, Avenue John F. Kennedy C. / Montalbán 9 L - 1855 Luxembourg E - 28014 Madrid Local Representatives Taiwan: Concord Capital Management Corp. Switzerland: 9F, No. 176, Sec. 1 Swiss & Global Asset Management AG Keelung Rd. Hardstraße 201 Taipei P.O. Box CH - 8037 Zurich Sweden: MFEX Mutual Fund Paying agent in Germany: Exchange AB DekaBank Deutsche Girozentrale Linnégatan 9-11 Hahnstraße 55 SE - 114 47 Stockholm D - 60528 Frankfurt / Main Cyprus: Information agent in Germany: Cyprus Development Bank Public Company Ltd. Swiss & Global Asset Management Kapital AG 50 Arch. Makarios III Avenue Taunusanlage 15 P.O. Box 21415 D - 60325 Frankfurt / Main CY - 1508 Nicosia Austria: Erste Bank der oesterreichischen Sparkassen AG Graben 21 A - 1010 Vienna 5 Notes to the Semi-annual Report Legal information Julius Baer Multistock (the “Company”) was incorporated on 1 December 1989 for an indefinite period. It is organised as a Société d’Investissement à Capital Variable (open-ended investment company – SICAV) under the law of 10 August 1915 of the Grand Duchy of Luxembourg, as amended. It has been registered under Part I of the amended law of 17 December 2010 as an undertaking for collective investment in transferable securities (UCITS). The Company is registered under number B-32188 in the Luxembourg Trade and Companies Register. The Company has its registered office at 25, Grand-Rue, L - 1661 Luxembourg. Share categories The following share classes are issued at present: - A shares: Shares with distribution of income and/or capital gains. - B shares: Shares without distribution of income and/or capital gains - C shares (for institutional investors): Shares without distribution of income and/or capital gains - Ca shares (for institutional investors): Shares with distribution of income and/or capital gains. - E shares (for specific distributors, as defined in the prospectus): Shares without distribution of income and/or capital gains - R shares (for specific distributors, as defined in the prospectus): Shares without distribution of income and/or capital gains - Ra shares (for specific distributors, as defined in the prospectus): Shares with distribution of income and/or capital gains. “A”, “B”, “C” and “R” shares may also bear the additional "h" (currency-hedged share categories). Accounting principles Presentation of the semi-annual report The financial statements of the Company have been prepared in compliance with the legal requirements for investment funds in Luxembourg. The present report has been prepared on the basis of the last net asset value calculation at the end of the accounting period (hereinafter: NAV = Net Asset Value). Aggregation Each sub-fund of the Company prepares
Load more

Recommended publications
  • 2020 Annual Report HIGHLIGHTS SHAREHOLDER MANAGEMENT SUSTAINABILITY CORPORATE COMPENSATION FINANCIAL APPENDIX LETTER COMMENTARY REPORT GOVERNANCE REPORT REPORT 2
    2020 Annual Report HIGHLIGHTS SHAREHOLDER MANAGEMENT SUSTAINABILITY CORPORATE COMPENSATION FINANCIAL APPENDIX LETTER COMMENTARY REPORT GOVERNANCE REPORT REPORT 2 CONTENTS #TogetherStrong Highlights 3 #TogetherStrong is a tag-name that covers #TogetherStrong aptly describes how we countless initiatives we took to address progressed through and emerged from this Letter to shareholders 7 pressing needs in the dental community extraordinary year. Management commentary 11 in 2020. Straumann Group in brief 12 Strategy in action 17 #TogetherStrong is forward-looking; it Products, solutions and services 21 It started with a website offering scientific expresses purpose, teamwork, courage, Innovation 26 and practical information to help Markets 29 determination, perseverance, moving Business performance (Group) 35 customers and staff through the corona forward and succeeding in turbulent Business performance (Regions) 38 virus crisis. Soon it became a holistic, Business performance (Financials) 44 surroundings – themes that are captured Share performance 46 omni-channel response including a in the pictures and contents of this report. Risk management 49 massive education platform. Sustainability report 57 The #TogetherStrong concept has Corporate governance 80 extended to thousands of activities Compensation report 107 and millions of communications. It demonstrates how the events of 2020 Financial report 123 fuelled our resourcefulness, innovation Appendix 184 and passion for creating opportunities. Global Reporting Initiative (GRI) 185 GRI content
    [Show full text]
  • Verily Forms Strategic Alliances with Novartis, Otsuka, Pfizer and Sanofi
    Verily Forms Strategic Alliances with Novartis, Otsuka, Pfizer and Sanofi to Transform Clinical Research Leading biopharmaceutical organizations join Project Baseline initiative to engage more patients and clinicians in research and speed evidence generation South San Francisco, CA -- May 21, 2019 -- Verily, an Alphabet company, today announced strategic alliances with Novartis (NYSE: NVS), Otsuka (NYSE: OTSKY), Pfizer Inc. (NYSE: PFE) and Sanofi (EURONEXT: SAN, NASDAQ: SNY) to develop digitally innovative, patient-centered clinical research programs using Project Baseline’s evidence generation platform and tools. The Baseline Platform is designed to engage more patients and clinicians in research, increase the speed and ease of conducting studies and collect more comprehensive, higher quality data, including outside the four walls of a clinic. Across the United States, the number of people participating in clinical research -- including clinical trials and observational studies -- is less than 10% of the population.1 In addition to low participation, challenges in research include data fragmentation, inefficient operations and limited value for patients. Alongside academic research institutions, patient-advocacy groups and health systems, Verily and its industry partners aim to implement a more patient-centric, technology-enabled approach to research, and increase the number and diversity of clinical research participants. They will also explore novel approaches to generating real-world evidence using the Baseline Platform to collect, organize and activate health information from electronic health records, sensors and other digital sources. Over the coming years, Novartis, Otsuka, Pfizer and Sanofi each plan to launch clinical studies leveraging the platform across diverse therapeutic areas, such as cardiovascular disease, oncology, mental health, dermatology and diabetes.
    [Show full text]
  • The Future of Digital Transformation and Innovation Unconference
    The Future of Digital Transformation and Innovation unConference 6 October 2016 USERNAME: PASSWORD: Practical Solutions Your Business for the 4th Industrial Revolution Brussels, Belgium, by The Conference Board Celebrating its 100 Year Anniversary! CONFIRMED SPEAKERS Brian Anderson Associate Program Director The Demand Institute ( jointly operated by The Conference Board and Nielsen ) Andrea Bonime-Blanc CEO GEC Risk Advisory Lindsey Canning Partner, Intellectual Property White & Case LLP London Bonnie Cheuk Director, Global Head of Digital, Knowledge & Social Collaboration Euroclear Kieran Conlon VP Sales & Services International Globoforce Martin Curley Former VP & Director Intel Labs Europe Intel Corporation David Dab Chief Innovation Officer ING Belgium Wim De Waele CEO Eggsplore John Higgins Director General Digital Europe Richard Hughes Director of Social Strategy BroadVision Joshua Jost Chief Storyteller Anderson Walsh Spencer Mark Leiter Chairman Leiter & Company Bertrand Liard Partner, Intellectual Property White & Case LLP Paris Jacquelyn MacLennan Partner, Competition White & Case LLP Brussels and London Ann Mettler Head of European Political Strategy Centre European Commission Dragan Pendic Head of Digital & Data Trust RelianceACSN Wil Schoenmakers Management Group PA Consulting Philippe Trichet Digital Expert Director Boston Consulting Group Nicolas van Zeebroeck Innovation and Digital Business Solvay Brussels School Philip Weiss Author of “Hyperthinking”, Founder ZN Sponsors WHY? WHO? Digital is set to revolutionize the The unConference is designed for 400+ C-suite and senior level executives, world. Is your company set for this? leading different functions in large organizations and different industries. Businesses have always changed—in reaction to changes in the marketplace WHAT? or in capabilities. But digital The event will be an integrated blend of transformation presents a new 1.
    [Show full text]
  • Market Notice Date: 14 November 2019 Market Notice Number: 112/2019
    Market Notice Date: 14 November 2019 Market Notice Number: 112/2019 Equiduct Universe Change Please see today's changes below effective 18 November 2019: Trading Reporting MIC Settlement Trading Settlement Tick Size Change/ Security Name ISIN Home Market Symbol Country Currency Currency table Action ABB LTD ABBNz CH0012221716 XSWX EQTB CH CHF CHF ESMA_E Deletion ABB ABBs CH0012221716 XSTO EQTB SE SEK SEK ESMA_E Deletion ADECCO SA ADENz CH0012138605 XSWX EQTC CH CHF CHF ESMA_E Deletion AMS AG AMSz AT0000A18XM4 XSWX EQTC CH CHF CHF ESMA_E Deletion ARYZTA AG ARYNz CH0043238366 XSWX EQTB CH CHF CHF ESMA_E Deletion JULIUS BAER GRUPPE AG BAERz CH0102484968 XSWX EQTC CH CHF CHF ESMA_E Deletion BALOISE-HLDGS BALNz CH0012410517 XSWX EQTC CH CHF CHF ESMA_D Deletion BARRY CALLEBAUT AG BARNz CH0009002962 XSWX EQTC CH CHF CHF ESMA_D Deletion BB BIOTECH BBZAd CH0038389992 XETR EQTB DE EUR EUR ESMA_D Deletion BB BIOTECH BIONz CH0038389992 XSWX EQTB CH CHF CHF ESMA_D Deletion BASILEA PHARMACEUTICA AG BSLNz CH0011432447 XSWX EQTC CH CHF CHF ESMA_D Deletion BUCHER INDUSTRIES BUCNz CH0002432174 XSWX EQTC CH CHF CHF ESMA_D Deletion COMPAGNIE FINANCIERE RICHEMONT CFRz CH0210483332 XSWX EQTC CH CHF CHF ESMA_E Deletion CLARIANT CLNz CH0012142631 XSWX EQTC CH CHF CHF ESMA_E Deletion CEMBRA MONEY BANK AG CMBNz CH0225173167 XSWX EQTC CH CHF CHF ESMA_D Deletion CREDIT SUISSE GROUP AG CSGNz CH0012138530 XSWX EQTC CH CHF CHF ESMA_E Deletion DKSH HOLDING DKSHz CH0126673539 XSWX EQTC CH CHF CHF ESMA_D Deletion DORMA+KABA HOLDING AG DOKAz CH0011795959 XSWX EQTC CH CHF
    [Show full text]
  • Longer Term Investments Medical Devices
    Longer Term Investments Medical devices Chief Investment Office GWM | 11 April 2019 6:53 pm BST Lachlan Towart, Analyst; Stefan R Meyer, Analyst • The aging population and growth of the over-65 age group will create more opportunities for companies selling medical products and devices. • Other drivers of this industry include better penetration in emerging markets due to improved infrastructure, innovative new treatments, increased affordability due to rising per-capita GDP and a growing prevalence of "lifestyle diseases" such as obesity due to urbanization. • We identified five key markets for implantable or wearable devices, including consumer products such as hearing aids, dental implants and corrective lenses. We estimate their total market size at USD 114.8bn with a rate of potential growth in the mid-single digits. • The theme is relatively defensive and should appeal to quality- focused investors. We recommend exposure to it via a diversified portfolio of stocks across our preferred markets and segments. Medical devices can assist in the treatment of many conditions. Some reduce the risk of a treated condition worsening, perhaps as an alternative to drug therapy; others improve users' quality of life or functionality; and still others can solve problems untreatable with drugs. Devices like joint replacements effectively offer permanent long-term solutions (i.e. a cure). Medical devices are primarily used by the over-65 age group, whose growth will outpace the broader population's over the coming decades. Demand is also supported by the rise of "lifestyle diseases" like obesity, itself related to urbanization. The medical device industry has matured, but still represents a substantial opportunity, in our view.
    [Show full text]
  • 312.1.Full.Pdf
    Ann Rheum Dis: first published as 10.1136/annrheumdis-2021-eular.1066 on 19 May 2021. Downloaded from 312 Scientific Abstracts Acknowledgements: This study was funded by Novartis Pharma AG. The found many DEGs from baseline with GUS treatment and none with PBO. These authors thank Richard Karpowicz, PhD, of Health Interactions, Inc, for providing included genes related to B-, T-, NK-, and plasma cells (increased by GUS) and medical writing support/editorial support, which was funded by Novartis Pharma- neutrophils, monocytes, eosinophils, and macrophages (decreased by GUS), ceuticals Corporation, East Hanover, NJ, in accordance with Good Publication suggestive of a partial normalization of immune cell composition in whole blood. Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). Conclusion: Using whole transcriptome profiling, we detected DEGs in blood Disclosure of Interests: Gurjit S. Kaeley Consultant of: Novartis Pharmaceuti- samples obtained from PsA pts vs. healthy controls, suggesting a dysregulation cals Corporation, Georg Schett Speakers bureau: AbbVie, Bristol Myers Squibb, of immune cell profiles in PsA. The majority of these disease-associated genes Celgene, Janssen, Eli Lilly, Novartis, and Pfizer, Consultant of: AbbVie, Bristol were modulated by GUS, with directionality toward a normalization of whole Myers Squibb, Celgene, Janssen, Eli Lilly, Novartis, and UCB, Grant/research blood transcriptomic signatures. support from: Bristol Myers Squibb, Celgene, GSK, Eli Lilly, and Novartis, Philip REFERENCES: G Conaghan Consultant of: or Speakers bureau: AbbVie, AstraZeneca, Bristol [1] Deodhar A et al. Lancet. 2020;395:1115. Myers Squibb, Eli Lilly, EMD Serono, Flexion Therapeutics, Galapagos, Gilead, [2] Mease P et al. Lancet. 2020;395:1126. Novartis, and Pfizer, Grant/research support from: UK National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Dennis McGona- Table 1.
    [Show full text]
  • Nextgen WEALTH MANAGERS 30.06.2020
    ESG Swiss Equities Certificate NextGen WEALTH MANAGERS 30.06.2020 Objective & Strategy ESG Swiss Equities certificate invests in a financial and ESG criteria scored weighted index. The index tracks Swiss financially sound companies that generate investment performance and integrate corporate social responsability, ethics and sustainability characteristics in order to have a long term positive environmental, social, governance (ESG) impact. It aims to be a reference by providing a specific solution that allows capital markets to redirect investment flows toward a more sustainable economy. Only companies with a financial and ESG score equal or above the median are eligible for inclusion in the ESG Swiss Equities Index. The dynamic strategy is based upon a synthetic notional investment allocation and reallocation in the Index Components following a specific and monitored process of eligibility defined by NextGen Wealth Managers SA. Monthly Comment Classification In June, the ESG Swiss Equities certificate registered a performance of 2.78% compared to Asset Type Equities May's 2.78%. The certificate’s benchmark, the Swiss Performance Index (SPI), performed Region Switzerland positively at 1.55% against 2.86% in the previous month. Since the beginning of the year, the Style ESG Systematic two baskets stand at -8.11% for the certificate and -3.13% for the benchmark. Since inception, cumulated performances are respectively at 12.34% and 34.73% (representing annualized performances of 2.72% and 7.12%) for annualized volatilities of 13.07% and 9.59%. The portfolio's allocation in large capitalization companies remains around 36% against 9% in middle capitalization companies and 54% in small capitalization companies.
    [Show full text]
  • Julius Baer Multicooperation Annual Report 2005 As at June 30, 2005 (Audited)
    Julius Baer Multicooperation Annual Report 2005 as at June 30, 2005 (audited) Subscriptions are only valid if made on the basis of the current Prospectus, the latest Annual Report and the latest Semi-Annual Report if published thereafter. The Articles of Association, the valid Prospectus and the Annual and Semi-Annual Reports may be obtained free of charge at the representative in Switzerland and the respective paying agent. Only the German version of the present Annual Report has been reviewed by the independent auditor. Consequently, the independent auditor's report only refers to the German version of the Report; other versions result from a conscientious translation made under the responsibility of the Board. In case of differences between the German version and the translation, the German version shall be the authentic text. AN INVESTMENT FUND DOMICILED IN LUXEMBOURG Representative in Switzerland: Julius Baer Investment Funds Services Ltd., Zurich Paying agent in Switzerland: Bank Julius Bär & Co. AG, Bahnhofstrasse 36, Postfach, CH - 8010 Zurich Paying agent in Germany: Bank Julius Bär (Deutschland) AG, Messe Turm, Friedrich-Ebert-Anlage 49, Postfach 15 01 52, D - 60061 Frankfurt on the Main Paying agent in Austria: Erste Bank der oesterreichischen Sparkassen AG, Graben 21, A - 1010 Vienna Contents Page Organisation and Management 4 Independent Auditor's Report 5 Notes to the Financial Statements 6 Julius Baer Multicooperation (Umbrella Fund) MCOO Julius Baer Multicooperation - Emerging Markets Value Stock Fund HESF Julius Baer Multicooperation
    [Show full text]
  • Bekanntmachung Auf Keyinvest Bezugsrechtsemission AMS AG
    Bekanntmachung auf KeyInvest Bezugsrechtsemission AMS AG Rights issue AMS AG Im Zusammenhang mit der Kapitalerhöhung der AMS AG (Bloomberg Code: AMS SE) durch Bezugsrechtsemission wurden die Bedingungen der unten genannten Produkte der UBS AG, per 16. März 2020 angepasst. Die detaillierten Informationen befinden sich in der entsprechenden Produktedokumentation (Termsheets). With regard to the rights issue of AMS AG (Bloomberg Code: AMS SE), UBS AG will adjust the terms of the following products as of 16th March 2020. Detailed information can be found in the respective product documentation (Termsheets). ISIN Name CH0406766680 PERLES Plus on AMS AG CH0434739725 Kick-In Certificate on AMS AG / U-Blox / ABB CH0434739717 Kick-In Certificate on AMS AG / U-Blox / ABB CH0524660716 8.40% p.a. Callable Kick-In GOAL on AMS AG / Logitech / Temenos CH0391676241 PERLES Plus on AMS AG CH0405218907 PERLES Plus on AMS AG CH0428536335 9.00% p.a. ER Worst of Kick-In GOAL on AMS AG / Temenos / OC Oerlikon CH0437181537 Kick-In Certificate on AMS AG / Autoneum Holding AG / Dufry AG CH0524663124 10.20% p.a. ER Kick-In GOAL on AMS AG CH0522755518 6.00% p.a. Callable Kick-In GOAL on AMS AG / Kühne + Nagel / Swatch I / Richemont / LafargeHolcim CH0509384506 6.496023402505% p.a. Kick-In GOAL on AMS AG / Credit Suisse / Swiss Re CH0512543437 FACTOR CERTIFICATE ON AMS AG CH0512543445 FACTOR CERTIFICATE ON AMS AG CH0512547974 FACTOR CERTIFICATE ON AMS AG CH0527058983 FACTOR CERTIFICATE ON AMS AG CH0453246909 CHF MINI-FUTURE ON AMS AG CH0521942109 CHF EQUITY-WARRANT
    [Show full text]
  • Retirement Strategy Fund 2060 Description Plan 3S DCP & JRA
    Retirement Strategy Fund 2060 June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA ACTIVIA PROPERTIES INC REIT 0.0137% 0.0137% AEON REIT INVESTMENT CORP REIT 0.0195% 0.0195% ALEXANDER + BALDWIN INC REIT 0.0118% 0.0118% ALEXANDRIA REAL ESTATE EQUIT REIT USD.01 0.0585% 0.0585% ALLIANCEBERNSTEIN GOVT STIF SSC FUND 64BA AGIS 587 0.0329% 0.0329% ALLIED PROPERTIES REAL ESTAT REIT 0.0219% 0.0219% AMERICAN CAMPUS COMMUNITIES REIT USD.01 0.0277% 0.0277% AMERICAN HOMES 4 RENT A REIT USD.01 0.0396% 0.0396% AMERICOLD REALTY TRUST REIT USD.01 0.0427% 0.0427% ARMADA HOFFLER PROPERTIES IN REIT USD.01 0.0124% 0.0124% AROUNDTOWN SA COMMON STOCK EUR.01 0.0248% 0.0248% ASSURA PLC REIT GBP.1 0.0319% 0.0319% AUSTRALIAN DOLLAR 0.0061% 0.0061% AZRIELI GROUP LTD COMMON STOCK ILS.1 0.0101% 0.0101% BLUEROCK RESIDENTIAL GROWTH REIT USD.01 0.0102% 0.0102% BOSTON PROPERTIES INC REIT USD.01 0.0580% 0.0580% BRAZILIAN REAL 0.0000% 0.0000% BRIXMOR PROPERTY GROUP INC REIT USD.01 0.0418% 0.0418% CA IMMOBILIEN ANLAGEN AG COMMON STOCK 0.0191% 0.0191% CAMDEN PROPERTY TRUST REIT USD.01 0.0394% 0.0394% CANADIAN DOLLAR 0.0005% 0.0005% CAPITALAND COMMERCIAL TRUST REIT 0.0228% 0.0228% CIFI HOLDINGS GROUP CO LTD COMMON STOCK HKD.1 0.0105% 0.0105% CITY DEVELOPMENTS LTD COMMON STOCK 0.0129% 0.0129% CK ASSET HOLDINGS LTD COMMON STOCK HKD1.0 0.0378% 0.0378% COMFORIA RESIDENTIAL REIT IN REIT 0.0328% 0.0328% COUSINS PROPERTIES INC REIT USD1.0 0.0403% 0.0403% CUBESMART REIT USD.01 0.0359% 0.0359% DAIWA OFFICE INVESTMENT
    [Show full text]
  • CA Signed Novartis 315 Settlement Agreement Signed California
    STATE SETTLEMENT AGREEMENT I. PARTIES This Settlement Agreement (the "Agreement") is entered into between the State of California ("the State") and Novartis Pharmaceuticals Corporation ("Novartis"), collectively, "the Parties." II. PREAMBLE As a preamble to this Agreement, the Parties agree to the following: A. At all relevant times, Novartis, (a subsidiary of Novartis International AG, which is headquartered in Basel, Switzerland) was a corporation with its principal place of business in East Hanover, New Jersey, distributed, marketed and/or sold pharmaceutical products in the United States, including drugs sold under the trade names of Lotrel, Valturna, Starlix, Tekamlo, Diovan, Diovan HCT, Tekturna, Tekturna HCT, Exforge, and Exforge HCT (the "Covered Drugs"). B. On January 5, 2011 , Oswald Bilotta, (the "Relater") filed a sealed qui tam action, which was subsequently amended on October 19, 2012, as of right on April 3, 2013 (pursuant to an unopposed motion dated March 21 , 2013), and on July 10, 2013 (pursuant to a stipulation dated July 8, 2013) (the "Civil Action") in the United States District Court for the Southern District of New York captioned United States of America et al. , ex rel. Oswald Bilotta et al. v. Novartis Pharmaceuticals Corporation Civil Action No. 1 l-cv-00071 , alleging, inter alia, that Novartis violated the False Claims Act ("FCA") and the Anti-Kickback Statute, 42 U.S.C. §I320a-7b(b) (the "AKS"), by paying doctors remuneration to prescribe the drugs Lotrel, Valturna, Starlix, Tekturna, Tekturna HCT, Diovan, Diovan HCT, Exforge, and Exforge HCT through the mechanism ofspeaker program honoraria and related misconduct. Novartis-315 Page 1 of 19 On April 26, 2013, the United States intervened in the Civil Action against Novartis by filing a Notice of Election to Intervene and Complaint-in-Intervention, in which it is asserted that claims against Novartis under the FCA and common law.
    [Show full text]
  • E 01 Pr..Sident
    Dokument 1 25.03.2004 8:36 Uhr Seite 2 2003 Dokument 1 25.03.2004 8:36 Uhr Seite 3 Dokument 1 25.03.2004 8:37 Uhr Seite 4 Key Financial Data of the Lindt & Sprüngli Group 2003 2002 Change Income statement in % Consolidated sales CHF million 1 800.5 1 680.5 7.1 EBITDA CHF million 265.2 242.4 9.4 in % of consolidated sales % 14.7 14.4 EBIT CHF million 188.7 170.8 10.5 in % of consolidated sales % 10.5 10.2 Net income CHF million 122.4 101.9 20.1 in % of consolidated sales % 6.8 6.1 Cash flow CHF million 206.2 178.3 15.6 in % of consolidated sales % 11.5 10.6 Balance Sheet Total assets CHF million 1 592.3 1 492.1 6.7 Current assets CHF million 1 042.2 940.0 10.9 in % of total assets % 65.5 63.0 Fixed assets CHF million 550.1 552.1 –0.4 in % of total assets % 34.5 37.0 Long-term liabilities CHF million 382.6 379.8 0.7 in % of total assets % 24.0 25.5 Shareholders’ equity CHF million 728.7 608.9 19.7 in % of total assets % 45.8 40.8 Investments in fixed assets CHF million 75.1 77.6 –3.2 in % of cash flow % 36.4 43.5 Employees Average number of employees 6 011 6 029 –0.3 Sales per employee 1 000 CHF 299.5 278.7 7.5 Data per share Net income per share/10 PC CHF 562 468 20.1 Cash flow per share/10 PC CHF 947 819 15.6 Dividend per share/10 PC 1) CHF 140 110 27.3 Payout ratio % 24.9 23.5 Shareholders’ equity per share/10 PC CHF 3 345 2 799 19.5 Price registered share 31.12.
    [Show full text]